Celltrion Eyes Remsima SC Launches In Canada And Australia

Company On Track To Launch At Least One Biosimilar Every Year By 2030

Start Launch
Celltrion is focused on launching subcutaneous infliximab in Canada and Australia, and adalimumab in Europe • Source: Alamy

More from Products

More from Generics Bulletin